Acquired by Q32 Bio in Apr 2024
FIXX - Homology Medicines, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Bedford,
United States
Type: Equity
FIXX price evolution
FIXX
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $39.27 | $29.11 | $76.8 | $39.45 |
| Short term investments | $43.39 | $74.19 | $50.27 | $110.57 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $83.91 | $106.64 | $131.34 | $153.58 |
| Long term investments | $13.96 | $17.32 | $23.04 | |
| Property, plant & equipment | $0.65 | $19.47 | $20.68 | $21.26 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.65 | $33.43 | $38 | $44.3 |
| Total investments | $43.39 | $88.14 | $67.59 | $133.61 |
| Total assets | $84.56 | $140.06 | $169.34 | $197.88 |
| Current liabilities | ||||
| Accounts payable | $3.23 | $7.8 | $3.39 | $3.63 |
| Deferred revenue | $0.35 | |||
| Short long term debt | $1.32 | $1.78 | $1.7 | $1.63 |
| Total current liabilities | $11.57 | $25.29 | $22.94 | $18.51 |
| Long term debt | $26.56 | $27.02 | $27.48 | |
| Total noncurrent liabilities | $26.56 | $27.02 | $27.48 | |
| Total debt | $1.32 | $28.34 | $28.72 | $29.1 |
| Total liabilities | $11.57 | $51.85 | $49.96 | $45.98 |
| Shareholders' equity | ||||
| Retained earnings | -$542.1 | -$525.98 | -$493.02 | -$457.98 |
| Other shareholder equity | -$0.01 | -$0.04 | -$0.09 | -$0.18 |
| Total shareholder equity | $72.99 | $88.21 | $119.38 | $151.9 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $39.27 | $0.02 | $110.33 | $218.71 |
| Short term investments | $43.39 | $141.04 | $47.49 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $83.91 | $181.01 | $191.91 | $219.56 |
| Long term investments | $25.81 | |||
| Property, plant & equipment | $0.65 | $21.64 | $17.86 | $42.9 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.65 | $47.45 | $19.81 | $44.17 |
| Total investments | $43.39 | $166.85 | $47.49 | |
| Total assets | $84.56 | $228.47 | $211.72 | $263.74 |
| Current liabilities | ||||
| Accounts payable | $3.23 | $1.14 | $2.37 | $4.72 |
| Deferred revenue | $1.16 | $4.36 | $37.77 | |
| Short long term debt | $1.32 | $1.56 | $0.25 | $2.5 |
| Total current liabilities | $11.57 | $22.58 | $17.23 | $22.66 |
| Long term debt | $27.92 | $23.69 | $12.94 | |
| Total noncurrent liabilities | $27.92 | $24.84 | $45.08 | |
| Total debt | $1.32 | $29.48 | $23.93 | $15.44 |
| Total liabilities | $11.57 | $50.49 | $42.07 | $67.74 |
| Shareholders' equity | ||||
| Retained earnings | -$542.1 | -$429.14 | -$424.13 | -$328.37 |
| Other shareholder equity | -$0.01 | -$0.4 | -$0.01 | |
| Total shareholder equity | $72.99 | $177.98 | $169.65 | $196 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.35 | $0.8 | ||
| Cost of revenue | ||||
| Gross Profit | $0.35 | $0.8 | ||
| Operating activities | ||||
| Research & development | $1.51 | $17.52 | $22.98 | $19.99 |
| Selling, general & administrative | $7.9 | $6.84 | $8.19 | $8.32 |
| Total operating expenses | $12.1 | $31 | $31.17 | $28.31 |
| Operating income | -$12.1 | -$31 | -$30.82 | -$27.51 |
| Income from continuing operations | ||||
| EBIT | -$16.12 | -$32.95 | -$35.04 | -$28.84 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$16.12 | -$32.95 | -$35.04 | -$28.84 |
| Income (for common shares) | -$16.12 | -$32.95 | -$35.04 | -$28.84 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.16 | $3.21 | $33.97 | $2.7 |
| Cost of revenue | ||||
| Gross Profit | $1.16 | $3.21 | $33.97 | $2.7 |
| Operating activities | ||||
| Research & development | $62 | $98.35 | $93.08 | $100.39 |
| Selling, general & administrative | $31.26 | $38.14 | $36.84 | $32.57 |
| Total operating expenses | $102.58 | $136.49 | $129.92 | $132.97 |
| Operating income | -$101.43 | -$133.28 | -$95.95 | -$130.26 |
| Income from continuing operations | ||||
| EBIT | -$112.96 | -$4.29 | -$95.76 | -$128.69 |
| Income tax expense | $0.71 | |||
| Interest expense | ||||
| Net income | ||||
| Net income | -$112.96 | -$5 | -$95.76 | -$128.69 |
| Income (for common shares) | -$112.96 | -$5 | -$95.76 | -$128.69 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$16.12 | -$32.95 | -$35.04 | -$28.84 |
| Operating activities | ||||
| Depreciation | $0.97 | $0.5 | $0.58 | $0.59 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.85 | $1.71 | $2.4 | $2.37 |
| Total cash flows from operations | -$21.57 | -$24.94 | -$23.66 | -$26.05 |
| Investing activities | ||||
| Capital expenditures | $0.22 | $0.34 | -$0.23 | |
| Investments | $31.5 | -$23.1 | $61 | $31.6 |
| Total cash flows from investing | $31.72 | -$22.76 | $61 | $31.37 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.01 | $0.02 | $0 | $0.15 |
| Net borrowings | ||||
| Total cash flows from financing | $0.01 | $0.02 | $0 | $0.15 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $10.15 | -$47.69 | $37.34 | $5.47 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$112.96 | -$5 | -$95.76 | -$128.69 |
| Operating activities | ||||
| Depreciation | $2.64 | $2.6 | $9.54 | $8.9 |
| Business acquisitions & disposals | $130 | |||
| Stock-based compensation | $7.32 | $13.05 | $17.25 | $13.25 |
| Total cash flows from operations | -$96.23 | -$113.66 | -$109.75 | -$94.33 |
| Investing activities | ||||
| Capital expenditures | $0.33 | -$1.28 | -$2.4 | -$3.73 |
| Investments | $101 | -$92 | -$48.39 | $208.63 |
| Total cash flows from investing | $101.33 | $36.72 | -$50.79 | $204.9 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.18 | $0.6 | $52.17 | $53.09 |
| Net borrowings | ||||
| Total cash flows from financing | $0.18 | $0.6 | $52.17 | $53.09 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $5.28 | -$76.35 | -$108.37 | $163.66 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 58.02M |
| Revenue | $1.16M |
|---|---|
| EBITDA | -$110.32M |
| EBIT | -$112.96M |
| Net Income | -$112.96M |
| Revenue Q/Q | -100.00% |
| Revenue Y/Y | -63.97% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 1.26 |
| Cash/Share | 0.68 |
| EPS | -$1.95 |
|---|---|
| ROA | -76.34% |
| ROE | -104.48% |
| Debt/Equity | 0.16 |
|---|---|
| Net debt/EBITDA | 0.25 |
| Current ratio | 7.25 |
| Quick ratio | 7.25 |